Merck scores key phase 3 win for novel ulcerative colitis therapy

Merck & Co Inc. MRK on Monday said its investigational therapy tulisokibart achieved the primary endpoint in a Phase 3 study in moderately to severely active ulcerative colitis (UC), marking what the ...

Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

SPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p<0.0001) from baseline at Week 12 in Robart’s ...

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart ...
Pharmabiz

Merck announces positive top line results from a Phase 3 study on tulisokibart

Merck, known as MSD outside of the United States and Canada, announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart (MK-7240), an ...
Medscape

Hyperbaric Oxygen Therapy Improves Refractory Colitis Outcomes

Hyperbaric oxygen therapy was well tolerated in treatment-refractory ulcerative colitis and enhanced clinical outcomes alongside improved bowel perfusion.